Thrombocytopenia

Hematology·MeSH: Thrombocytopenia

Prevalence

30.0 / 100K

47 drugs in development·31 companies·10 clinical trials

Drug Pipeline by Phase

Approved(8)

Drug	Company
avatrombopag	GYRE THERAPEUTICS, INC. (GYRE)
azacitidine	Amneal Pharmaceuticals, Inc. (AMRX)
contiva	GYRE THERAPEUTICS, INC. (GYRE)
doptelet	AKORN INC (AKRX)
promacta	Novartis AG (NVS)
promacta kit	Novartis AG (NVS)
tavalisse	RIGEL PHARMACEUTICALS INC (RIGL)
triamcinolone acetonide	Teva Pharmaceutical Industries Limited (TEVA)

Phase 3(18)

Drug	Company
angiomax	SCICLONE PHARMACEUTICALS INC (SCLN)
bms-986393	Juno Therapeutics, Inc. (JUNO)
cad-1005	Cadrenal Therapeutics, Inc. (CVKD)
doptelet	Dova Pharmaceuticals Inc. (DOVA)
elritercept (KER-050)	Keros Therapeutics, Inc. (KROS)
hmpl-523	HUTCHMED (China) Ltd (HMDCF)
hmpl-523	HUTCHMED (China) Limited (HCM)
hmpl-523	HUTCHMED (China) Limited (HCM)
ianalumab	Merus N.V. (MRUS)
Ianalumab	Novartis AG (NVS)
intravenous immunoglobulins	GH Research PLC (GHRS)
nipocalimab	GH Research PLC (GHRS)
Nipocalimab	ENANTA PHARMACEUTICALS INC (ENTA)
Nipocalimab	ADMA BIOLOGICS, INC. (ADMA)
Rilzabrutinib	Sanofi (SNY)
romiplostim	AMGEN INC (AMGN)
tak-079	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
tak-079	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)

Phase 2(11)

Drug	Company
anti- human monoclonal antibody	Rallybio Corp (RLYB)
bms-986353	Juno Therapeutics, Inc. (JUNO)
budoprutug	Climb Bio, Inc. (CLYM)
eltrombopag	Novartis AG (NVS)
Eltrombopag	Novartis AG (NVS)
inca000585	Incyte Corp. (INCY)
rlyb212	Rallybio Corp (RLYB)
sar445088	Sanofi (SNY)
thrombopoietin receptor agonist	Merus N.V. (MRUS)
thrombopoietin receptor agonist	NOVARTIS AG (NVSEF)
thrombopoietin receptor agonist	Novartis AG (NVS)

Phase 1(1)

Drug	Company
fludarabine	Juno Therapeutics, Inc. (JUNO)

Early Phase 1(1)

Drug	Company
QT-019C	Filana Therapeutics Inc. (FLNA)

Phase 1/Phase 2(3)

Drug	Company
cid-103	CASI Pharmaceuticals, Inc. (CASIF)
povetacicept	ALPINE IMMUNE SCIENCES, INC. (ALPN)
zugo-cel	CRISPR Therapeutics AG (CRSP)

Phase 4(5)

Drug	Company
Efgartigimod	ARGENX SE (ARGX)
Efgartigimod IV	ARGENX SE (ARGX)
efgartigimod iv or efgartigimod ph20 sc	ARGENX SE (ARGX)
ianalumab	Novartis AG (NVS)
Pirtobrutinib	ELI LILLY & Co (LLY)

BioSniper tracks 47 drugs in development for Thrombocytopenia across 31 companies.

There are 10 clinical trials targeting Thrombocytopenia tracked by BioSniper.

The estimated prevalence of Thrombocytopenia is approximately 30.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.